Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.53 | N/A | +6.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.53 | N/A | +6.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, indicating a focus on long-term growth. They did not provide specific revenue guidance.
We are pleased with our EPS performance this quarter.
While we didn't provide revenue guidance, we remain focused on our strategic initiatives.
Krystal Biotech's earnings report showed a positive surprise in EPS, which indicates stronger-than-expected profitability. However, the stock fell by 5.85% following the announcement, likely due to the lack of revenue guidance and uncertainty in future performance. Investors may be cautious as the company navigates its strategic plans without clear revenue expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHEVRON CORP NEW
Aug 2, 2024